Basics Akebia Therapeutics, Inc. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. IPO Date: March 24, 2018 Sector: Healthcare Industry: Biotech Market Cap: $669.72M Activated in VL: True Average Daily Range Avg Daily Range: $0.13 | 3.57% Avg Daily Range (30 D): $0.08 | 3.75% Avg Daily Range (90 D): $0.07 | 3.48% Institutional Daily Volume Avg Daily Volume: 2.63M Avg Daily Volume (30 D): 3.94M Avg Daily Volume (90 D): 3.53M Trade Size Avg Trade Size (Sh.): 315 Avg Trade Size (Sh.) (30 D): 348 Avg Trade Size (Sh.) (90 D): 342 Institutional Trades Total Inst.Trades: 830 Avg Inst. Trade: $1.65M Avg Inst. Trade (30 D): $.62M Avg Inst. Trade (90 D): $1.1M Avg Inst. Trade Volume: .47M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.56M Avg Closing Trade (30 D): $.63M Avg Closing Trade (90 D): $.89M Avg Closing Volume: 466.63K         News Apr 2, 2025 @ 9:00 AM AVEROA Receives Positive Opinion from the European... Source: N/A Mar 20, 2025 @ 2:17 AM Akebia Therapeutics Announces Pricing of Public Of... Source: N/A Feb 7, 2025 @ 10:52 AM $10.7 Billion Healthcare Mobile Robots Market Outl... Source: Na Jul 10, 2024 @ 11:04 AM Unicycive Therapeutics Announces Initial Positive ... Source: Unicycive Therapeutics, Inc. May 9, 2024 @ 12:10 PM Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses... Source: Zacks Equity Research Financials   TTM Q1 2025 Q4 2024 Basic EPS $-.22 $.03 $-.11 Diluted EPS $-.22 $.03 $-.11 Revenue $ 184.91M $ 57.34M $ 46.5M Gross Profit $ 125.71M $ 49.71M $ 26.13M Net Income / Loss $ -45.31M $ 6.11M $ -22.8M Operating Income / Loss $ -22.02M $ 13.51M $ -14.31M Cost of Revenue $ 59.2M $ 7.63M $ 20.37M Net Cash Flow $ 70.48M $ 61.51M $ 17.86M PE Ratio